Thus the occurrence of liver cancer may be mediated by treatment with APOBEC3B agonist therapy at the HBV stage by restricting viral replication or inhibiting the development of liver cancer by interfering with the non-enzyme-dependent function of APOBEC3B in the early stages of liver cancer. The gene discussed is APOBEC3B; the disease is liver cancer.